Bioais reports positive results re multiple sclerosis

Bioais has reported positive results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis.

In previously published work1, a recombinant fusion protein of Bioasis’ proprietary xB3™ peptide with an interleukin-1 receptor antagonist (xB3™-IL-1RA) demonstrated efficient delivery of effective concentrations of IL-1RA to the brain eliciting analgesia in a neuropathic pain animal model. Systemic administration of IL-1RA alone did not elicit analgesia.